FDA clears Sanofi's Type 3 Gaucher therapy Infilbray
Sanofi's Infilbray has become the first drug to treat neurological symptoms of rare lysosomal storage disorder Type 3 Gaucher disease (GD3) in the US.
Infilbray (venglustat) – a first-in-class brain-penetrating glucosylceramide synthase (GCS) inhibitor taken as a once-daily pill – can be used in adults and paediatric patients with GD3 who weigh at least 15 kg, according to the FDA.
The drug is designed to counteract the build-up of toxic metabolites caused by a deficiency of the enzyme glucocerebrosidase in GD3, which leads to muscular and cognitive symptoms.
The central nervous system impact of G3D differentiates it from the other main form of Gaucher disease (Type 1 or GD1), which mainly affects peripheral organs and tissues, and for which there are a number of GCS enzyme replacement therapies (ERTs) available, allowing patients to have a normal lifespan. Type 2 (GD2) is an ultra-rare form that strikes in infancy, has devastating consequences on the brain, and is generally fatal by around age two.
G3D – which is the most common form globally, albeit less common than GD1 in the US and Europe – also causes peripheral tissue damage that can be addressed by ERT, allowing patients to have near-normal longevity. Until now, however, there was nothing to be done about the CNS complications for GD3 patients, of whom there are an estimated 1,000 to 1,500 in the US.
Sanofi is already a big player in Gaucher disease, selling the ERT Cerezyme (imiglucerase) for all three types, as well as Cerdelga (eliglustat), an oral therapy used as a first-line therapy for certain patients with GD1.
In the LEAP2MONO trial, Infilbray achieved statistically significant improvements in neurological symptoms over 52 weeks, measured using the SARA and RBANS scales, compared to standard infusions of Cerezyme. It also performed as well as ERT on non-CNS symptoms of G3D, including spleen and liver volume and haemoglobin levels.
"Patients living with Type 3 Gaucher disease face a long and difficult road to accurate diagnosis, often going years without answers while neurological manifestations progress," said Aviva Rosenberg, co-founder and chief executive of the Gaucher Community Alliance.
The Infilbray approval "marks a long-awaited advancement for those experiencing devastating neurological symptoms of Type 3 Gaucher disease," she added.
Sanofi hasn't revealed its launch plans or pricing yet for Infilbray, which has been approved with label warnings for suicidal ideation and behaviour, lens opacification in paediatric patients, and embryofoetal toxicity.
Infilbray is also under regulatory review for GD3 in the EU and Japan.
Once billed as a blockbuster, commercial prospects for the drug have been winnowed down following failed trials in various other indications – including autosomal dominant polycystic kidney disease (ADPKD), GM2 gangliosidosis, Parkinson's disease, and Fabry disease – and analysts now put its peak sales potential at $300 million to $500 million a year.
